Table 1 Potential targets and drugs against the interplay between cancer cells and adipocytes
From: Adipocytes: active facilitators in epithelial ovarian cancer progression?
Target | Agent | Mechanism | Anti-cancer effect | Reference |
|---|---|---|---|---|
PPARγ | GW9662 | Suppression of adipocyte differentiation | Inhibition of the anti-PD-L1 effect of adipocytes | [106] |
adipogenesis | Sulforaphane | Suppression of adipocyte differentiation | Inhibition of the cancer promoting effect of adipocytes | [111] |
β-adrenergic | Propranolol | Suppression of lypolysis in adipocytes | Inhibition of the EOC promoting effect of adipocytes | [15] |
lipid droplet | Myricetin | Suppression of the lipid droplets accumulation | Inhibition of the EOC promoting effect of adipocytes | |
β-oxidation | Trimetazidine | Inhibition of fatty acid oxidation | Inhibition of the EOC promoting effect of adipocytes | |
CD36 | Sulfo-N-succinimidyl oleate | Inhibition of fatty acid uptake of EOC cells | Inhibition of the EOC progression and metastasis induced by adipocytes | [114] |
Leptin | pegylated leptin peptide receptor antagonist 2 | Leptin antagonist | Inhibition of ovarian cancer peritoneal metastasis | [115] |
IL-6 | Tocilizumab | Monoclonal antibody against IL-6R | Enhancement of the immunity in patients with recurrent EOC | [116] |
VEGF-A | Bevacizumab | Monoclonal antibody against VEGF-A | Improvement of the survival in patients with ovarian cancer | [81] |